Issue 4 2007

Featuring

In vivo drug target validation using rnai
Jost Seibler, Head of Technology Development, Artemis Pharmaceuticals and Frieder Schwenk, Principal Scientist, University of Applied Science, Department of Applied Natural Sciences, Gelsenkirchen, Germany

RNAi Europe Preview

How will micrornas affect the drug discovery landscape?
Dr. Neil Clarke and Dr. Mark Edbrooke, GlaxoSmithKline Research and Development, Hertfordshire, UK

Proteomics - Hupo Preview

Biology and data capture in the life sciences industry
Neil Kipling, Biology and Data Capture in the Life Sciences Industry

Academic Contribution to high-content screening for functional and chemical genomics
Kerstin Korn and Eberhard Krausz (corresponding author), Head, HT-Technology Development Studio (TDS), Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG)

The impact of automation on drug discovery
William P. Janzen, President and COO, Amphora Discovery

ELRIG/SBS Preview

Implementation of an enterprise eln: a case study
Dr. Simon Weston, Programme Delivery Leader, Discovery, AstraZeneca

DDT Preview

Implementing near infrared spectroscopy as a pat tool in the biopharmaceutical industries
Payal Roy-Choudhury, PhD Student, Fermentation Centre, strathclyde Institute of Pharmacy & Biomedical Science, Glasgow, UK

A "PAT" on the back for rapid microbiological methods (RMMs)
Robert Johnson, CEO, Dialogue

PAT roundtable - PAT in the pharmaceutical industry

If you wish to view the magazine in PDF format (size: 2.10 MB), please click HERE